ARRY-162 (binimetinib) is a reversible MEK1/2 inhibitor which is often used in conjunction with encorafenib in BRAF V600E-mutant metastatic melanoma, NSCLC, and colorectal cancer (107–109). This evidence concerns the gene BRAF and metastatic melanoma.